Managing patients first with triple therapy and switching…
““Managing patients first with triple therapy and switching to a biologic plus methotrexate in those who do not have an adequate response may be more cost-effective, without adversely affecting clinical outcomes. A recent study did not find a difference between biologics and triple therapy in time to return to work ( 2 ). Cost-effectiveness trials and long-term follow-up studies are needed to assess the durability of intermediate outcomes (such as disease activity) with patient-centered outcomes.””
About This Quote
This interpretation was drafted with AI assistance. It is one reading of the quote, not the author's own explanation.
Evaluating treatment strategies for rheumatoid arthritis suggests triple therapy may be as cost‑effective as biologics without harming outcomes, but more long‑term data are needed.
In simple terms: Triple therapy could be cheaper and equally effective, yet evidence is limited.
Key Takeaway
Consider cost and efficacy when choosing RA treatments.
Themes
health economics
pharmacology
clinical outcomes
Mood
analytical
pragmatic
Type
clinical
research
When to use this quote
- rheumatology clinics
- insurance policy decisions
- patient counseling
- research funding proposals
Key Concepts
cost‑effectiveness
patient‑centered care
long‑term durability
Questions to Reflect On
- What long‑term outcomes matter most to patients?
- How can clinicians balance cost with uncertain durability?
A Different Perspective
Limited data on long‑term durability and real‑world adherence may affect conclusions.